Latest News about NVS
Recent news which mentions NVS
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 31, 2024
From Benzinga
Why Is European Pharma Giant Novartis Stock Trading Lower Today?
January 31, 2024
From Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
From Benzinga
Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 31, 2024
From Benzinga
Earnings Scheduled For January 31, 2024
January 31, 2024
From Benzinga
3 Hidden Healthcare Stocks Poised for a Breakout This Year
January 30, 2024
From InvestorPlace
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
From Benzinga
From Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
From Benzinga
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
January 11, 2024
From Benzinga
What's Been Happening With Cytokinetics Stock?
January 09, 2024
From Benzinga
From Benzinga
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
From Benzinga
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
January 08, 2024
From Benzinga
Voyager Therapeutics Stock Tanked After-Hours - Here's Why
January 04, 2024
From Benzinga
From InvestorPlace
From Benzinga
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
December 28, 2023
From Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
From InvestorPlace
These 3 Big Pharma Stocks Are Making Big Plays With AI
December 22, 2023
From Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
From Benzinga
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
From Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
From Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.